Pieter C Smits

Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions.

Patrick W Serruys, Muzaffer Degertekin, Pedro A Lemos, 2004, Journal of the American College of Cardiology.

Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes

Bernard Chevalier, Patrick W Serruys, Yoshinobu Onuma, 2010, Circulation.

Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?

Patrick W Serruys, Yoshinobu Onuma, Richard Rapoza, 2012, European heart journal.

Clinical, Angiographic, and Procedural Predictors of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Complex Patients: An Evaluation From the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Study

Patrick W Serruys, Dick M. Goedhart, Pedro A Lemos, 2004, Circulation.

A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents.

Bernard Chevalier, Patrick W Serruys, Yoshinobu Onuma, 2010, JACC. Cardiovascular interventions.

Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography.

Patrick W Serruys, Yoshinobu Onuma, Richard Rapoza, 2011, JACC. Cardiovascular interventions.

Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up.

Bernard Chevalier, Patrick W Serruys, Richard Rapoza, 2011, JACC. Cardiovascular interventions.

Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial.

Bernard Chevalier, Jan J Piek, Patrick W Serruys, 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.

Bernard Chevalier, Patrick W Serruys, Yoshinobu Onuma, 2011, Journal of the American College of Cardiology.

Coronary Restenosis After Sirolimus‐Eluting Stent Implantation: Morphological Description and Mechanistic Analysis From a Consecutive Series of Cases

Patrick W Serruys, Muzaffer Degertekin, Joost Daemen, 2003, Circulation.

Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin-E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry

Patrick W Serruys, Muzaffer Degertekin, Joost Daemen, 2004, Circulation.

Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience.

Patrick W Serruys, Muzaffer Degertekin, Jeroen Vos, 2003, Journal of the American College of Cardiology.

Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up.

Patrick W Serruys, Don Poldermans, Robert-Jan M van Geuns, 2003, Journal of the American College of Cardiology.